TRPV1: A Potential Therapeutic Target in Type 2 Diabetes and Comorbidities?
Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Standard
TRPV1 : A Potential Therapeutic Target in Type 2 Diabetes and Comorbidities? / Gram, Dorte X; Holst, Jens J; Szallasi, Arpad.
I: Trends in Molecular Medicine, Bind 23, Nr. 11, 11.2017, s. 1002-1013.Publikation: Bidrag til tidsskrift › Review › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - TRPV1
T2 - A Potential Therapeutic Target in Type 2 Diabetes and Comorbidities?
AU - Gram, Dorte X
AU - Holst, Jens J
AU - Szallasi, Arpad
N1 - Copyright © 2017 Elsevier Ltd. All rights reserved.
PY - 2017/11
Y1 - 2017/11
N2 - With an estimated 422 million affected patients worldwide in 2016, type 2 diabetes (T2D) has reached pandemic proportions and represents a major unmet medical need. T2D is a polygenic disease with a chronic, low-grade inflammatory component. Second-generation transient receptor potential vanilloid-1 (TRPV1) antagonists are potent anti-inflammatory agents with proven clinical safety. In rodent models of T2D, TRPV1 blockade was shown to halt disease progression and improve glucose metabolism. Thus, we propose that TRPV1 antagonists merit further study as novel therapeutic approaches to potentially treat T2D and its comorbidities.
AB - With an estimated 422 million affected patients worldwide in 2016, type 2 diabetes (T2D) has reached pandemic proportions and represents a major unmet medical need. T2D is a polygenic disease with a chronic, low-grade inflammatory component. Second-generation transient receptor potential vanilloid-1 (TRPV1) antagonists are potent anti-inflammatory agents with proven clinical safety. In rodent models of T2D, TRPV1 blockade was shown to halt disease progression and improve glucose metabolism. Thus, we propose that TRPV1 antagonists merit further study as novel therapeutic approaches to potentially treat T2D and its comorbidities.
KW - Journal Article
KW - Review
U2 - 10.1016/j.molmed.2017.09.005
DO - 10.1016/j.molmed.2017.09.005
M3 - Review
C2 - 29137713
VL - 23
SP - 1002
EP - 1013
JO - Trends in Molecular Medicine
JF - Trends in Molecular Medicine
SN - 1471-4914
IS - 11
ER -
ID: 189623760